IceCure Medical gains after ProSense update, $5.5M placement
NEW YORK, June 18, 2026, 07:07 (EDT)
- IceCure ended trading Wednesday at $6.40, rising 200.47%. The stock was last seen at $7.27 before the bell at 6:59 a.m. EDT.
- The company set the price for a $5.5 million private placement at $3.00 a share, including warrants. It plans to use the money for working capital and general corporate purposes.
- IceCure reported its active U.S. ProSense install base for breast cancer cryoablation jumped 70% after getting FDA marketing approval, according to a separate update. Nasdaq is closed Friday for Juneteenth.
IceCure Medical shares looked headed for another choppy day Thursday, after the Israeli medical-device firm gave a U.S. commercial update and announced fresh financing. The stock, listed on Nasdaq, jumped 200.47% to $6.40 on Wednesday. Early pre-market data from Webull put it at $7.27 as of 6:59 a.m. EDT.
This pick-up matters for investors now as they look at early U.S. adoption of ProSense following FDA marketing clearance, all while fresh equity supply hangs over the shares. Cryoablation uses freezing to destroy tissue—offering a less invasive option than surgery in certain cases.
IceCure said Wednesday it’s selling 1,833,334 ordinary shares and Series D and Series E warrants to one institutional investor with a focus on healthcare. The total price is $3.00 per share with attached warrants. The deal is a private placement, not a public offering.
The company is targeting about $5.5 million in gross proceeds before fees, with the deal set to close on or around June 18, as long as typical closing conditions are met. Funds raised will go to working capital and general corporate needs. The warrants have a $3.00 exercise price; Series D warrants run for five years, Series E warrants for one year.
IceCure reported Wednesday its active U.S. install base for ProSense, aimed at breast cancer cryoablation, is up 70% since getting FDA clearance in October 2025. The company says the procedure has now been used in Los Angeles, New York, Atlanta, Dallas, Detroit, Philadelphia, Phoenix, Memphis, and other cities.
Chief Executive Eyal Shamir said the company is in the “early stages of a significant commercial opportunity” in U.S. breast cancer cryoablation. Shamir also said physician training and education matter, along with getting wider patient access. PR Newswire
IceCure said ProSense is cleared for local treatment of low-risk breast cancer with adjuvant endocrine therapy in women 70 and older, even those who can’t have surgery. Adjuvant endocrine therapy is a hormone-blocking treatment after a local procedure to lower the risk of the cancer coming back.
Commercial pressure, not just regulatory hurdles, is driving the test. Big med-tech players already have ablation devices out, like Boston Scientific’s ICEfx system for minimally invasive cryoablation, and Varian/Siemens Healthineers with their CryoCare Touch system. IceCure is making a push for market share, focusing on its breast-cancer indication and an office-based setup.
But the new financing could put a lid on the rally if traders eye dilution over the added cash. IceCure is also planning, pending shareholder signoff and Nasdaq OK, to lower the strike price for some March 2026 warrants to $3.00 from $16.50. That would put more shares on the table if exercised later. The company flagged risks in sales execution, funding, regulatory issues, intellectual property, and instability in Israel and the Middle East as factors that might impact results.
Nasdaq’s regular session opens at 9:30 a.m. EDT and ends at 4 p.m. EDT. The exchange will be closed Friday, June 19, for Juneteenth. Pre-market runs 4 a.m. to 9:30 a.m., with extended-hours trading often thinner and more volatile, Nasdaq says.
